Genomic Health (GHDX) Reports In-Line Q2 EPS

Genomic Health (NASDAQ: GHDX) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $82 million versus the consensus estimate of $81.27 million.

GUIDANCE:

Genomic Health sees FY2016 EPS of ($0.37)-($0.55), versus the consensus of ($0.45). Genomic Health sees FY2016 revenue of $325-335 million, versus prior guidance of $320-335 million and the consensus of $330.5 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea